Beetham Thomas W. 4

4 · Viridian Therapeutics, Inc.\DE · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
[F2][F5]
2026-03-03+9,409→ 16,409 total
Tax Payment
Common Stock
[F5]
2026-03-03$29.32/sh−3,138$92,006→ 13,271 total
Award
Stock Option (Right to Buy)
[F1]
2026-03-02+176,550→ 176,550 total
Exercise: $30.25Exp: 2036-03-02→ Common Stock (176,550 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-03-02+35,300→ 35,300 total
→ Common Stock (35,300 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-03-03−9,409→ 28,227 total
→ Common Stock (9,409 underlying)

Footnotes (5)

[F1]The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
[F2]Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
[F3]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F4]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F5]Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

Signature

Jennifer Tousignant, Attorney-in-fact|2026-03-04

Documents

1 file